Results
In our previous reports, we showed that intestinal dysbiosis mediates the development of experimental AIP by activating pDCs, which have the ability to produce large amounts of IFN-α and IL-33 [6, 14, 16, 19, 20]. This study aimed to clarify alterations in gut microbiota that have been poorly defined in type 1 AIP patients.